Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States

Advances in Therapy

Volumn 24, Issue 2, 2007, Pages 273-290

  Valentine, William J ^a   Erny Albrecht, K M ^a   Ray, J A ^a   Roze, S ^a   Cobden, D ^b   Palmer, A J ^a  

^a IQVIA   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Cost effectiveness; Insulin; Insulin detemir; Insulin glargine; NPH insulin; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; STATINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG COST; DRUG SUBSTITUTION; FEMALE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; QUALITY ADJUSTED LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; UNITED STATES; VALIDATION PROCESS;

ADMINISTRATION, ORAL; BODY MASS INDEX; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; LIFE EXPECTANCY; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 34250894365     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849895     Document Type: Article

References (29)

1. American Diabetes Association. Available at: http://www.diabetes.org.com. Accessed February 7, 2006.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
3. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531-537.
4. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006;4:23-31.
5. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144:465-474.
6. Oglesby AK, Secnik K, Barron J, Al Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006; 4:1.
7. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11:559-564.
8. Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract. 2006;60:1138-1145.
9. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003; 26:917-932.
10. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
11. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29:1269-1274.
12. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. (Online Early Articles). doi:10.1111/j.1463-1326.2006.00674.x.
13. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(suppl 1):S5-S26.
14. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(suppl 1):S27-S40.
15. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia. 2002;45:S13-S17.
16. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Endocrinol Diabetes. 2002;110:10-16.
17. Tarn T, Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections. 2004;10: 5-15.
18. Davies R, Wittrup-Jensen KU, Peters JR, Morrissey M, Currie CJ. The impact on health-related quality of life (EQ-5Dindex) in people with type 1 diabetes who experience severe hypoglycemia. Eur Assoc Study Diabetes. 2005.
19. National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance - No. 53. Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes - Insulin Glargine. London, UK: NICE; 2002.
20. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327-340.
21. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005;59:1345-1355.
22. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
23. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
24. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201.
25. Pieber TR, Treichel H-C, Hompesch B, et al. Direct comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensified insulin therapy. Diabetic Med. 2006; Submitted.
26. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
27. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003;25:1017-1038.
28. Hart AC, Richards B (eds). DRG Guidebook. A Comprehensive Resource to the DRG Classification System. 17th ed. Reston, Va: Ingenix Publishing Group; 2000.
29. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care. 2003;26:2305-2310.